Literature DB >> 10082217

Visceral chemical nociception in mice lacking mu-opioid receptors: effects of morphine, SNC80 and U-50,488.

I Sora1, X F Li, M Funada, S Kinsey, G R Uhl.   

Abstract

Writhing responses to intraperitoneal acetic acid administration and their modulation by mu-, kappa- and delta-opioid receptor agonists were compared in wild-type and mu-opioid receptor knockout mice. Unpretreated homozygous knockout mice displayed less writhing than wild-type mice. U-50,488 [trans-3,4-dichloro-N-methyl-N-[2-(1-pyrolidinyl)cyclohexyl]-benze neacetamide]) reduced writhing responses in wild-type and knockouts. Morphine and SNC80 [(+)-4-[9-alpha-R)-alpha-(2S,5RO-4-allyl-2,5-dimethyl-1-piperaziny l)-3-methoxybenzyl]-N,N-diethylbenzamide] were effective in wild-type mice but ineffective in knockouts. Mu-opioid receptors appear to play important roles in responses to this visceral nociceptive stimulus and its modulation by mu- and delta-opioid receptor agonists.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082217     DOI: 10.1016/s0014-2999(98)00933-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.

Authors:  S Stevens Negus; Marisa B Rosenberg; Ahmad A Altarifi; Robert H O'Connell; John E Folk; Kenner C Rice
Journal:  J Pain       Date:  2012-03-15       Impact factor: 5.820

2.  The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors.

Authors:  Matthew D Metcalf; Ajay S Yekkirala; Michael D Powers; Kelley F Kitto; Carolyn A Fairbanks; George L Wilcox; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2012-05-22       Impact factor: 4.418

Review 3.  Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.

Authors:  Wakako Fujita; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 4.  The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses.

Authors:  G R Uhl; I Sora; Z Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  The untranslated region of (mu)-opioid receptor mRNA contributes to reduced opioid sensitivity in CXBK mice.

Authors:  K Ikeda; T Kobayashi; T Ichikawa; T Kumanishi; H Niki; R Yano
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

Review 6.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

7.  Activity of mu- and delta-opioid agonists in vas deferens from mice deficient in MOR gene.

Authors:  R Maldonado; C Severini; H W Matthes; B L Kieffer; P Melchiorri; L Negri
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

8.  Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia.

Authors:  Yohann Bohren; Dzenan Karavelic; Luc-Henri Tessier; Ipek Yalcin; Claire Gavériaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Michel Barrot
Journal:  Eur J Pain       Date:  2009-12-28       Impact factor: 3.931

Review 9.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

10.  Opiate-agonist induced taste aversion learning in the Fischer 344 and Lewis inbred rat strains: evidence for differential mu opioid receptor activation.

Authors:  Catherine M Davis; Kenner C Rice; Anthony L Riley
Journal:  Pharmacol Biochem Behav       Date:  2009-06-07       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.